داروسازی دکتر عبیدی / Articles Posts / the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
داروسازی دکتر عبیدی / Articles Posts / the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study.
Here, we present the fi nal analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).
PDFادامه مطلبBiosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer.
We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castrationresistant prostate cancer who have received chemotherapy.
PDFادامه مطلبHormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers.
Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways.
PDFادامه مطلبارتباط علمی داروسازی دکتر عبیدی با کادر درمانی بهداشتی کشور گزینهای است که در نهایت منجر به ارائه راهکارهای درمانی بهتر و ارتقاء سطح سلامت جامعه میشود. بخش علمی وبسایت ویژه پزشکان، داروسازان، پرستاران و سایر اعضای محترم کادر درمانی بهداشتی در حال آمادهسازی است. به زودی در این بخش با مطالب علمی گردآوری شده از منابع علمی معتبر جهان در خدمت شما فرهیختگان گرامی خواهیم بود.